Skip to main content

Table 1 Demographic and baseline characteristics of the enrolled patients

From: The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer

Clinicopathological No. of patients
Characteristics n, (%)
Gender
 Male 43 (66.2)
 Female 22 (33.8)
ECOG performance status score
 0 21 (32.3)
 1 38 (58.5)
 2 6 (9.2)
Primary tumor location
 Head 32 (49.2)
 Body 13 (20.0)
 Tail 6 (9.2)
 Multicentric 14 (21.6)
No. of metastatic sites involved
 Median 1
 Range 1–4
Metastatic tumor sites
 Liver 53 (81.5)
 Lung 14 (21.5)
 Lymph nodes 19 (29.2)
 Peritoneum 15 (23.1)
 Others 7 (10.8)
Cycles of mFOLFIRINOX
 Median 8
 Range 1–12
  1. ECOG Eastern Cooperative Oncology Group, mFOLFIRINOX modified 5-fluorouracil, irinotecan, leucovorin, and oxaliplatin